Is NCT05827081 recruiting in Goodyear, AZ?

Yes, NCT05827081 is currently recruiting participants at its Goodyear, AZ location. This breast cancer clinical trial is actively enrolling qualified participants.

How do I join the breast cancer clinical trial in Goodyear?

To join this clinical trial in Goodyear, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Goodyear clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Breast Cancer Clinical Trial in Goodyear, AZ

About This Breast Cancer Study in Goodyear

The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBCFS), in a close to clinical practice patient population with HR-positive (HR+), HER2-negative (HER2-), Anatomic Stage Group III, IIB, and a subset of Stage IIA Early Breast Cancer (EBC).

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Participant is an adult, male or female ≥ 18 years of age at the time of informed consent form signature (IC).

Participant has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer (BC) based on the most recently analyzed tissue sample tested by a local laboratory prior to enrollment.

Participant has HER2- BC defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing based on the most recently analyzed tissue sample.

Participants may have already received any standard neoadjuvant and/or adjuvant ET, including tamoxifen or toremifene at the time of informed consent signature, but enrollment should occur within 36 months of prior ET start date and participants should have at least 3 years remaining of endocrine adjuvant therapy.

For participants with prior ET treatment \> 12 months, restaging is highly recommended (unless contradictory to local regulations) to rule out disease recurrence prior to enrollment.

The number of participants with prior ET between 12 and 36 months will be capped at 30%. The cap will not apply to Black or African American participants.

Participant has no contraindication to receive adjuvant ET in the study.

Participant after surgical resection where tumor was removed completely, with the final surgical specimen microscopic margins free from tumor, and belongs to one of the following categories:

Anatomic Stage Group III, or

Anatomic Stage Group IIB, or

A subset of Anatomic Stage Group IIA.

Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.

Participant has adequate bone marrow and organ function.

ECG values assessed by KardiaMobile-6L device, or standard 12-lead ECG per local investigator where KardiaMobile-6L cannot be used, as:

QTcF interval at Screening \< 450 msec (QT interval using Fridericia's correction).

Mean resting heart rate 50-99 beats per minute (determined from the ECG). Key

Exclusion Criteria

Participant with distant metastases of BC beyond regional lymph nodes (Stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery.

Participant is concurrently using other antineoplastic therapy with the exception of adjuvant ET.

Participant has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate participant participation in the clinical study or compromise compliance with the protocol, or limit life expectancy to ≤5 years.

Clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality.

Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial.

Women of child-bearing potential (CBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 21 days after stopping the treatment. Other inclusion/exclusion criteria may apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Goodyear?

Yes, this clinical trial (NCT05827081) has an active research site in Goodyear, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Breast Cancer Treatment Options in Goodyear, AZ

If you're searching for breast cancer treatment options in Goodyear, AZ, this clinical trial (NCT05827081) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Goodyear research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all breast cancer clinical trials near you to find additional studies recruiting in your area.

Breast Cancer Clinical Trial in Goodyear, AZ

Expert Care in Goodyear

IRB Approved

No-Cost Care

Apply for This Goodyear Location

Why Participate?

Simple Process